ACC 2026: dulaglutide promotes coronary plaque stabilisation in patients with T2D
Type 2 diabetes (T2D) and heart health have a complex and dependent relationship. New data presented at ACC 2026 suggests …
Post
-
-
Biogen uplifts rare disease pipeline with $5.6bn Apellis buyout
Biogen has forged a $5.6bn deal to acquire immunology and rare disease specialist Apellis Pharmaceuticals – marking another M&A milestone …
-
Eli Lilly outlays $7.8bn to acquire sleep drug biotech Centessa
Eli Lilly will acquire neuroscience specialist Centessa Pharmaceuticals in a deal worth up to $7.8bn, solidifying the drugmaker’s status as …
-
Telomir seeks FDA approval for Telomir-1 to treat breast cancer
Telomir Pharmaceuticals has submitted an investigational new drug application to the US Food and Drug Administration for Telomir-1 (Telomir-Zn), its …
-
ACC 2026: Sotatercept shows signal in CpcPH-HFpEF at lower dose
At the 2026 American College of Cardiology (ACC) Scientific Session in New Orleans, the phase II CADENCE trial reported results …
-
ACC 2026: Tonlamarsen lowers angiotensinogen without extra BP benefit
At the 2026 American College of Cardiology (ACC) Scientific Session in New Orleans, the KARDINAL phase II trial assessed tonlamarsen, …
-
Symeres and Ambagon collaborate for colorectal cancer molecules
Symeres has entered a collaboration with Ambagon Therapeutics on molecular glue research in colorectal cancer, aiming to address diseases considered …
-
Non-invasive diagnostics in endometriosis: at the cusp of a turning point
Endometriosis affects an estimated 10% of reproductive-age women worldwide. Early diagnosis is crucial for preventing disease progression, improving pain management, …
-
The rise of ADCs in oncology: how antibody drug conjugate therapies deliver precision
An antibody drug conjugate links a tumor-binding antibody to a potent small-molecule payload through a designed chemical linker. The aim …
-
Navigating commercial gaps to supercharge the UK life sciences sector
Off the northwestern coast of mainland Europe, there sits an island with big ambitions for its life sciences sector. Though small …
-
Teva receives FDA approval for Prolia biosimilar
Teva Pharmaceutical has announced the US Food and Drug Administration (FDA) approval for Ponlimsi (denosumab-adet) as a biosimilar to Prolia, …
-
Blackstone closes largest ever private funding investment round at $6.3bn
Private investment platform Blackstone closed a funding raise that has brought in $6.3bn in capital to support its ongoing life …
-
uBriGene and Cellinfinity BIO collaborate to accelerate in vivo CAR-T therapies
uBriGene Biosciences has signed a strategic partnership with Cellinfinity BIO to advance the clinical development of in vivo chimeric antigen …
-
ACC 2026: Baxdrostat lowers BP in uncontrolled hypertension
At the 2026 American College of Cardiology (ACC) Scientific Session in New Orleans, researchers presented a meta-analysis of randomized trials …
-
ACC 2026: Lorundrostat lowers BP but raises hyperkalemia risk
At the 2026 American College of Cardiology (ACC) Scientific Session in New Orleans, investigators from Brazil presented a systematic review …
